Short Interest in Agenus Inc. (NASDAQ:AGEN) Drops By 10.5%

Agenus Inc. (NASDAQ:AGEN) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 2,800,000 shares, a decrease of 10.5% from the October 15th total of 3,130,000 shares. Currently, 13.2% of the shares of the stock are short sold. Based on an average trading volume of 393,300 shares, the days-to-cover ratio is currently 7.1 days.

Agenus Stock Down 1.8 %

Shares of NASDAQ:AGEN opened at $2.72 on Friday. The company has a market cap of $63.81 million, a P/E ratio of -0.24 and a beta of 1.39. The business has a fifty day simple moving average of $4.70 and a 200-day simple moving average of $8.67. Agenus has a 52 week low of $2.58 and a 52 week high of $19.69.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd purchased a new position in shares of Agenus during the 2nd quarter worth about $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Agenus during the second quarter worth approximately $106,000. HighTower Advisors LLC boosted its holdings in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares during the period. Finally, State Street Corp increased its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 9,731 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Analyst Upgrades and Downgrades

AGEN has been the topic of a number of analyst reports. HC Wainwright decreased their price objective on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 12th. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, B. Riley lowered their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.